Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,039.55INR
3:16pm IST
Change (% chg)

Rs-12.35 (-0.60%)
Prev Close
Rs2,051.90
Open
Rs2,073.00
Day's High
Rs2,073.00
Day's Low
Rs2,032.50
Volume
532,870
Avg. Vol
796,076
52-wk High
Rs2,787.00
52-wk Low
Rs1,887.00

Select another date:

Mon, Jul 16 2018

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co

** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees

BUZZ-India's Dr.Reddy's rises on US drug hopes; UK rival Indivior cuts guidance

** Dr.Reddy's Laboratories Ltd rise as much as 3.8 pct to 2,387.65 rupees, its highest in 3 weeks

Indivior says 2018 profit to fall short after U.S. market hit

British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

UPDATE 2-Indivior gets breather after court extends order blocking generic rival

* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)

U.S. court extends Indivior's restraining order against Dr. Reddy's generic drug

June 29 British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.

BUZZ-India's Dr.Reddy's hits over 4-month high after U.S. FDA nod

** Shares of Dr. Reddy's Laboratories Ltd climb as much as 3.4 pct to 2,347.10 rupees - highest since Jan 30

Select another date: